Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[ ]  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01. Other Events

Exhibit 100 to this Current Report on Form 8-K contains documents formatted in XBRL (eXtensible Business Reporting Language) with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended July 2, 2006, filed with the Securities and Exchange Commission (SEC) on August 11, 2006. The information formatted in XBRL includes the (i) Condensed Consolidated Statements of Income for the three and six months ended July 2, 2006 and July 3, 2005, (ii) Condensed Consolidated Balance Sheets at July 2, 2006 and December 31, 2005, and (iii) Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2006 and July 3, 2005.

Users of this data are advised pursuant to Rule 401 of Regulation S-T that the financial information contained in the XBRL-Related Documents is unaudited and these are not the official financial statements of Pfizer Inc. as filed with the SEC. The purpose of furnishing these XBRL formatted documents is solely for the purpose of participation in the SEC's voluntary XBRL pilot program to test the related format and technology and, as a result, investors should continue to rely on the official filed version of the furnished documents and not rely on the information in this Current Report on Form 8-K, including Exhibit 100, in making investment decisions.

In accordance with Rule 402 of Regulation S-T, the information in this Current Report on Form 8-K, including Exhibit 100, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits
	The following exhibits are furnished herewith:
	Exhibit Number	Exhibit Description
	100	The following financial statements from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended July 2, 2006, filed on August 11, 2006, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income for the three and six months ended July 2, 2006 and July 3, 2005, (ii) the Condensed Consolidated Balance Sheets at July 2, 2006 and December 31, 2005, and (iii) the Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2006 and July 3, 2005.

SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
		PFIZER INC.
		By: /s/ Margaret M. Foran
		Margaret M. Foran
Dated: November 30, 2006		Title:  Senior Vice President-Corporate Governance
		Associate General Counsel and Corporate Secretary